biotech · Type 1 Diabetes Mellitus · Dehydration · HALO
HALOZYME THERAPEUTICS
HALOZYME THERAPEUTICS, INC.
HALOZYME THERAPEUTICS clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 12390 El Camino Real, San Diego, California 92130, US
- Founded
- 2021
- Employees
- 530
- Programs
- 45
- Drugs
- 33
- Patents
- 70
HALOZYME THERAPEUTICS projects
14 ClinicalTrials.gov programs sponsored by HALOZYME THERAPEUTICS.
HALOZYME THERAPEUTICS has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Chemophase
HALOZYME THERAPEUTICS, INC.
Superficial Bladder Cancer
1 trial -
Cohort 1: bococizumab 150 mg + rHuPH20
HALOZYME THERAPEUTICS, INC.
Healthy
1 trial -
Humalog
HALOZYME THERAPEUTICS, INC.
Diabetes Mellitus
1 trial -
Insulin Lispro
HALOZYME THERAPEUTICS, INC.
Diabetes Mellitus
1 trial -
Insulin aspart
HALOZYME THERAPEUTICS, INC.
Type 1 Diabetes Mellitus
1 trial -
Ondansetron
HALOZYME THERAPEUTICS, INC.
Healthy
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
NSCLC
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Cholangiocarcinoma Non-resectable
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Solid Tumor
2 trials -
PEGylated recombinant human hyaluronidase PH20
HALOZYME THERAPEUTICS, INC.
Non-small Cell Lung Cancer
1 trial -
Recombinant human hyaluronidase PH20 (rHuPH20)
HALOZYME THERAPEUTICS, INC.
Healthy
1 trial -
SC HYLENEX and Ceftriaxone
HALOZYME THERAPEUTICS, INC.
Healthy
1 trial -
rHuPH20
HALOZYME THERAPEUTICS, INC.
Healthy Volunteers
1 trial -
rHuPH20
HALOZYME THERAPEUTICS, INC.
Risk Factors for or a Diagnosis of Osteoporosis
1 trial
Frequently asked questions
How many clinical projects does HALOZYME THERAPEUTICS have?
14 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.